Akebia Therapeutics (AKBA) EBITDA Margin Growth (3y) (2020 - 2026)
Akebia Therapeutics (AKBA) EBITDA Margin Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn | 357.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 308.00 |
| Mar 31, 2026 | 5,521.00 |
| Dec 31, 2025 | -611.00 |
| Sep 30, 2025 | 11,104.00 |
| Jun 30, 2025 | -441.00 |
| Mar 31, 2025 | 7.84 Mn |
| Dec 31, 2024 | -7,374.00 |
| Sep 30, 2024 | 7,916.00 |
| Jun 30, 2024 | 12,996.00 |
| Mar 31, 2024 | 7,835.00 |
| Dec 31, 2023 | 38,897.00 |
| Sep 30, 2023 | 35,630.00 |
| Jun 30, 2023 | 17,687.00 |
| Mar 31, 2023 | 284.00 |
| Dec 31, 2022 | 31,944.00 |
| Sep 30, 2022 | 45,558.00 |
| Jun 30, 2022 | 23,159.00 |
| Mar 31, 2022 | -7.82 Mn |
| Dec 31, 2021 | 21,299.00 |
| Sep 30, 2021 | -6,021.00 |